Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mehul Shah

Pain Medicine Freehold, NJ Doctor of Osteopathy

NPI 1447577028 CMS profile 1302208

210 Mounts Corner Dr, Freehold, NJ 07728

Open in the dashboard

General payments

$8,355

145 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mehul Shah of Freehold, NJ is reported in the CMS Open Payments database as having received $8,355 across 145 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $76 3
2024 General $278 5
2023 General $280 5
2022 General $4,956 31
2021 General $771 27
2020 General $867 34
2019 General $1,126 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mehul Shah
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Mehul Shah were reported at $76. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Mehul Shah Pain Medicine median Middle half National median
2019 $1,126 $506 $144–$1,566 $163
2020 $867 $315 $96–$934 $114
2021 $771 $452 $134–$1,237 $132
2022 $4,956 $475 $124–$1,407 $149
2023 $280 $480 $136–$1,384 $160
2024 $278 $521 $164–$1,511 $164
2025 $76 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. SPR Therapeutics, Inc $4,023 5 payments
  2. Nevro Corp. $1,308 33 payments
  3. Boston Scientific Corporation $873 30 payments
  4. Abbott Laboratories $515 21 payments
  5. Stryker Corporation $334 2 payments
  6. Vertos Medical, Inc. $205 4 payments
  7. Medtronic, Inc. $199 4 payments
  8. BIOTRONIK NRO, Inc. $144 2 payments
  9. Djo, LLC $88 1 payment
  10. Scilex Pharmaceuticals Inc. $82 6 payments
  11. Other $585 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,468 142 payments
  2. Consulting Fee $3,600 1 payment
  3. Travel and Lodging $266 1 payment
  4. Education $21 1 payment
Products named General payments · program years 2019–2025
  1. SPRINT PNS System $4,023 5 payments
  2. Senza Spinal Cord Stimulation System $970 27 payments
  3. Omnia $338 6 payments
  4. AVS ANCHOR-L $334 2 payments
  5. SPECTRA WAVEWRITER $316 12 payments
  6. PROCLAIM $212 6 payments
  7. WaveWriter Alpha Prime 16 $166 4 payments
  8. INTELLIS ADAPTIVESTIM $145 1 payment
  9. Prospera $144 2 payments
  10. mild Device Kit $141 2 payments
  11. Other $1,597 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

196

Median for Pain Management: 951

Drug cost

$1,443

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 63 $480
Pregabalin Generic 15 $389
Cyclobenzaprine Hcl Generic 38 $210
Tizanidine Hcl Generic 46 $187
Meloxicam Generic 34 $176

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$228,032

Of which drugs: $3,662

Medicare patients

415

Average age 73

Services billed

3,338

250 women, 165 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 40%
Ischemic heart disease 34%
Chronic kidney disease 24%
Depression 24%
Osteoporosis 19%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 124 631 $490

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

145 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record